Stock listing

Knight Therapeutics, Inc.

Selected listing: A1XE7A · LSX · EUR · DE

Knight Therapeutics, Inc. (LS Exchange: A1XE7A), Health Technology. Latest release Oct 6, 2026: Knight Therapeutics Announces Regulatory Approval of NIKTIMVO®…

A1XE7A:LSXEURDEUpdated October 2, 2026

Ticker: LS Exchange: A1XE7A
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: LS Exchange
Currency: EUR

Latest news from Knight Therapeutics, Inc.

Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil

October 6, 2026

Knight Therapeutics Announces Launch of TAVALISSE® in Brazil

October 6, 2026

Knight Therapeutics Enters into Exclusive Distribution Agreement with Kyowa Kirin International for Poteligeo® (Mogamulizumab)

September 29, 2026

Knight Therapeutics Inc. places No. 345 on The Globe and Mail’s eighth annual ranking of Canada's Top Growing Companies

September 25, 2026

Knight Therapeutics Announces Regulatory Submission of GEMTESA® in Canada

September 15, 2026

All Knight Therapeutics, Inc. news →

Events

Replays

Knight Therapeutics Inc. (GUD) Q2 2026 Earnings Call
Thu, Aug 06, 2026 · 08:30 AM ET
Watch
Knight Therapeutics Inc. (GUD) Q1 2026 Earnings Call
Thu, May 07, 2026 · 08:30 AM ET
Watch
Knight Therapeutics Inc. (GUD) Q4 2025 Earnings Call
Thu, Mar 19, 2026 · 08:30 AM ET
Watch

Research Knight Therapeutics, Inc.

Knight Therapeutics, Inc. company profile

View the public company page for Knight Therapeutics, Inc. on 6ix.

Knight Therapeutics, Inc. news

Read company news and market updates connected to Knight Therapeutics, Inc..

Knight Therapeutics, Inc. investor events

Find investor webinars, events, and replay context for Knight Therapeutics, Inc..